Jeff Jones
Stock Analyst at Oppenheimer
(0.65)
# 3,779
Out of 4,829 analysts
88
Total ratings
17.95%
Success rate
-23.13%
Average return
Main Sectors:
Stocks Rated by Jeff Jones
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZURA Zura Bio | Maintains: Outperform | $19 → $17 | $1.21 | +1,304.96% | 4 | May 9, 2025 | |
| CRVS Corvus Pharmaceuticals | Reiterates: Outperform | $15 → $17 | $4.43 | +283.75% | 5 | May 9, 2025 | |
| IMCR Immunocore Holdings | Maintains: Outperform | $85 → $86 | $28.40 | +202.82% | 2 | May 8, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $60 → $56 | $6.45 | +768.22% | 9 | May 7, 2025 | |
| ALMS Alumis | Initiates: Outperform | $32 | $5.03 | +536.18% | 1 | Jan 30, 2025 | |
| EVH Evolent Health | Maintains: Outperform | $28 → $18 | $9.05 | +98.90% | 4 | Jan 24, 2025 | |
| CLRB Cellectar Biosciences | Downgrades: Perform | n/a | $0.25 | - | 5 | Dec 11, 2024 | |
| CATX Perspective Therapeutics | Maintains: Outperform | $22 → $16 | $2.35 | +580.85% | 7 | Nov 22, 2024 | |
| YMAB Y-mAbs Therapeutics | Initiates: Outperform | $23 | $3.89 | +491.26% | 1 | Nov 18, 2024 | |
| CMMB Chemomab Therapeutics | Reiterates: Outperform | $13 → $11 | $1.26 | +773.02% | 7 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 → $9 | $1.24 | +625.81% | 10 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $56 | $30.07 | +86.23% | 4 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $35 → $39 | $20.15 | +93.55% | 2 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $45 | $1.41 | +3,091.49% | 6 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $7.06 | - | 4 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.20 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 | $0.25 | +47,255.96% | 3 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $6.90 | - | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $0.88 | +1,599.72% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $75 | $1.05 | +7,042.86% | 2 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,600 → $1,100 | $1.49 | +73,725.50% | 2 | Nov 17, 2022 |
Zura Bio
May 9, 2025
Maintains: Outperform
Price Target: $19 → $17
Current: $1.21
Upside: +1,304.96%
Corvus Pharmaceuticals
May 9, 2025
Reiterates: Outperform
Price Target: $15 → $17
Current: $4.43
Upside: +283.75%
Immunocore Holdings
May 8, 2025
Maintains: Outperform
Price Target: $85 → $86
Current: $28.40
Upside: +202.82%
Corbus Pharmaceuticals Holdings
May 7, 2025
Maintains: Outperform
Price Target: $60 → $56
Current: $6.45
Upside: +768.22%
Alumis
Jan 30, 2025
Initiates: Outperform
Price Target: $32
Current: $5.03
Upside: +536.18%
Evolent Health
Jan 24, 2025
Maintains: Outperform
Price Target: $28 → $18
Current: $9.05
Upside: +98.90%
Cellectar Biosciences
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $0.25
Upside: -
Perspective Therapeutics
Nov 22, 2024
Maintains: Outperform
Price Target: $22 → $16
Current: $2.35
Upside: +580.85%
Y-mAbs Therapeutics
Nov 18, 2024
Initiates: Outperform
Price Target: $23
Current: $3.89
Upside: +491.26%
Chemomab Therapeutics
Nov 15, 2024
Reiterates: Outperform
Price Target: $13 → $11
Current: $1.26
Upside: +773.02%
Nov 8, 2024
Reiterates: Outperform
Price Target: $10 → $9
Current: $1.24
Upside: +625.81%
Sep 27, 2024
Maintains: Outperform
Price Target: $52 → $56
Current: $30.07
Upside: +86.23%
Sep 10, 2024
Reiterates: Outperform
Price Target: $35 → $39
Current: $20.15
Upside: +93.55%
Aug 8, 2024
Maintains: Outperform
Price Target: $48 → $45
Current: $1.41
Upside: +3,091.49%
Jun 7, 2024
Downgrades: Perform
Price Target: n/a
Current: $7.06
Upside: -
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.20
Upside: -
May 25, 2023
Maintains: Outperform
Price Target: $120
Current: $0.25
Upside: +47,255.96%
May 23, 2023
Downgrades: Perform
Price Target: n/a
Current: $6.90
Upside: -
May 11, 2023
Reiterates: Outperform
Price Target: $15
Current: $0.88
Upside: +1,599.72%
Mar 24, 2023
Reiterates: Outperform
Price Target: $75
Current: $1.05
Upside: +7,042.86%
Nov 17, 2022
Maintains: Outperform
Price Target: $1,600 → $1,100
Current: $1.49
Upside: +73,725.50%